Medtronic draws subpoena
This article was originally published in The Gray Sheet
Documents relating to the firm's cardiac rhythm management devices are subpoenaed by the Office of Inspector General for the Department of Health and Human Services in the district of California, Medtronic discloses in a quarterly financial report filed Dec. 9 with the Securities and Exchange Commission. Related documents include "revenue, sales, marketing and promotional documents, documents relating to reimbursement communications to customers pertaining to the devices, documents relating to scientific studies and registries pertaining to the devices, and documents relating to payments or items of value provided to customers," Medtronic explains. The firm says it will comply with the subpoena, which it received on Sept. 16. Medtronic received a separate subpoena in June from the New Jersey attorney general's office as part of an investigation into industry ties to clinical trial investigators (1"The Gray Sheet" Aug. 10, 2009)
You may also be interested in...
Johnson & Johnson/DePuy is the latest of four orthopedic device makers to acknowledge receipt of a subpoena from the New Jersey attorney general's office as part of an investigation into industry ties to clinical trial investigators
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.